LDH elevation

Functionally, co-culture assays showed that knockdown of CD70 in B-lymphoma cells reduced naive CD4+ and CD8+ T-cell subsets, whereas CD79BY197H transfected B-lymphoma cells enhanced tumor cell viability. Our findings comprehensively characterize FL/DLBCL and tFL molecularly, elucidating their distinct pathogenesis and rationalize CD70 and CD79B targeted immunotherapies.

PCBP2 suppresses MTUS1 expression via 3'UTR-mediated degradation, inhibiting pyroptosis and promoting ESCC progression, suggesting the PCBP2/MTUS1 axis as a potential therapeutic target to enhance chemotherapy efficacy.

An etoposide-containing CHOP variant (ECHOP/CHOEP, days 1-5) was initiated with parallel continuous renal replacement therapy (CVVHDF) to stabilize acid-base and electrolytes as a bridge to chemotherapy...A focused review of 18 recent case reports (2021-2025) suggests that timely, standardized antitumor therapy is frequently followed by a rapid, time-locked fall in lactate, whereas the absence of definitive oncologic treatment portends uniformly poor short-term outcomes. This case underscores that, in hemodynamically stable patients with refractory hyperlactatemia, early consideration of CWE and prompt tumor-directed therapy-supported by targeted organ support such as CRRT-offer the most reliable path to metabolic reversal and recovery.

P2, N=40, Completed, Fred Hutchinson Cancer Center | Active, not recruiting --> Completed

(2) The severity of ILD in anti-MDA5-positive DM patients was positively correlated with LDH, suggesting that LDH might serve as an effective assessment indicator to evaluate the changes in ILD in these patients. (3) Elevated LDH levels were a crucial indicator of poor prognosis in anti-MDA5-positive DM patients, warranting close attention from rheumatologists.

In HER2-negative advanced gastric cancer, a ≥26% increase in LDH following two treatment cycles serves as an independent prognostic risk factor. Combining baseline CPS with early LDH dynamics improves the identification of patients with aggressive disease and poor initial treatment response, thereby facilitating closer monitoring and prompt therapeutic reassessment for more personalized management.

A detailed prognostic factor analysis for overall survival and progression-free survival in selected groups of advanced non-small-cell lung cancer patients under chemo- or mono-immunotherapy identified five independent parameters: initial ECOG of zero, non-elevated LDH, non-elevated CRP, pretreatment PD-L1 positivity and absence of KEAP1-mutation. Our findings are especially helpful of estimating early treatment failure with aggressive lung cancer progression. This important investigation will be prospectively confirmed in a larger, more unselected population at our Cancer Centre.

P1/2, N=30, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended

P2/3, N=20, Not yet recruiting, Incyte Corp.

P2, N=17, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed | Trial completion date: Jun 2028 --> May 2025

P1/2, N=10, Not yet recruiting, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Mutated cases showed advanced Binet stages, elevated LDH, and reduced hemoglobin (HGB) and platelet (PLT) counts. These findings reveal a notable prevalence of NOTCH1 and SF3B1 mutations associated with adverse features, expanding the CLL mutational spectrum and offering valuable prognostic and therapeutic insights.